Market revenue in 2023 | USD 2.4 million |
Market revenue in 2030 | USD 5.6 million |
Growth rate | 13% (CAGR from 2023 to 2030) |
Largest segment | Pure prp |
Fastest growing segment | Leukocyte Rich PRP |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pure PRP, Leukocyte Rich PRP |
Key market players worldwide | Johnson & Johnson, Arthrex, Terumo Corp, Zimmer Biomet Holdings Inc, Stryker Corp, EmCyte Corporation, Dr. PRP USA, Juventix Regenerative Medical, APEX Biologix, Celling Biosciences |
Pure prp was the largest segment with a revenue share of 50% in 2023. Horizon Databook has segmented the Sweden platelet rich plasma (prp) market based on pure prp, leukocyte rich prp covering the revenue growth of each sub-segment from 2018 to 2030.
The Sweden PRP market is witnessing significant growth, driven by the rising prevalence of musculoskeletal conditions, including degenerative joint disease and osteoarthritis. PRP is considered an orthobiologic treatment and utilizes natural substances found in the human body to accelerate the healing process.
Swedish physicians often offer PRP therapy as an alternative when conventional treatments have proven ineffective for patients. The increasing awareness of PRP's effectiveness in treating musculoskeletal diseases, coupled with its minimally invasive nature and potential for improved patient outcomes, has contributed to its growing popularity in Sweden.
As a result, the market for PRP therapy for musculoskeletal conditions is expected to continue expanding, with a focus on providing innovative and efficient solutions for patients dealing with these health issues.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account